Stock Track | Tandem Diabetes Care Plunges 16.61% in Pre-market on Disappointing Q4 Results and Outlook

Stock Track

Feb 27, 2025

Tandem Diabetes Care (TNDM) stock experienced a significant pre-market plunge of 16.61% on Thursday, following the release of the company's fourth-quarter and full-year 2024 financial results that missed analysts' expectations.

The medical device maker reported an adjusted operating loss of $30.2 million for Q4, wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.

Looking ahead, Tandem Diabetes Care provided a gloomy outlook for the current year, further weighing on investor sentiment. The company expects an adjusted net loss of $1.20 per share on revenue of $1.01 billion for 2025, falling short of analysts' projections.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1146211312"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146211312\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1146211312?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146211312","market":"hk","top_or_hot":-1,"title":"Stock Track | Tandem Diabetes Care Plunges 16.61% in Pre-market on Disappointing Q4 Results and Outlook","media":"Stock Track","content":"<p>Tandem Diabetes Care (TNDM) stock experienced a significant pre-market plunge of 16.61% on Thursday, following the release of the company's fourth-quarter and full-year 2024 financial results that missed analysts' expectations.</p>\n\n<p>The medical device maker reported an adjusted operating loss of $30.2 million for Q4, wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.</p>\n\n<p>Looking ahead, Tandem Diabetes Care provided a gloomy outlook for the current year, further weighing on investor sentiment. The company expects an adjusted net loss of $1.20 per share on revenue of $1.01 billion for 2025, falling short of analysts' projections.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tandem Diabetes Care Plunges 16.61% in Pre-market on Disappointing Q4 Results and Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tandem Diabetes Care Plunges 16.61% in Pre-market on Disappointing Q4 Results and Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 17:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tandem Diabetes Care (TNDM) stock experienced a significant pre-market plunge of 16.61% on Thursday, following the release of the company's fourth-quarter and full-year 2024 financial results that missed analysts' expectations.</p>\n\n<p>The medical device maker reported an adjusted operating loss of $30.2 million for Q4, wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.</p>\n\n<p>Looking ahead, Tandem Diabetes Care provided a gloomy outlook for the current year, further weighing on investor sentiment. The company expects an adjusted net loss of $1.20 per share on revenue of $1.01 billion for 2025, falling short of analysts' projections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"Tandem Diabetes","start_time":0,"source_url":"","article_id":"1146211312","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146211312","pubTimestamp":1740648650,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tandem Diabetes Care  stock experienced a significant pre-market plunge of 16.61% on Thursday, following the release of the company's fourth-quarter and full-year 2024 financial results that missed analysts' expectations.The medical device maker reported an adjusted operating loss of $30.2 million for Q4, wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, missing the consensus estimate of a $14.9 million loss. The ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"Tandem Diabetes"},"translate_title":"由于第四季度业绩和前景令人失望，Tandem Diabete Care盘前暴跌16.61%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":1},"content_text":"Tandem Diabetes Care (TNDM) stock experienced a significant pre-market plunge of 16.61% on Thursday, following the release of the company's fourth-quarter and full-year 2024 financial results that missed analysts' expectations.\nThe medical device maker reported an adjusted operating loss of $30.2 million for Q4, wider than analysts' estimate of a $17.6 million loss. Additionally, the adjusted net loss for the quarter came in at $28.8 million, missing the consensus estimate of a $14.9 million loss. The disappointing results were primarily driven by weaker-than-expected sales and higher costs.\nLooking ahead, Tandem Diabetes Care provided a gloomy outlook for the current year, further weighing on investor sentiment. The company expects an adjusted net loss of $1.20 per share on revenue of $1.01 billion for 2025, falling short of analysts' projections.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}